Navitus Takes GLP-1s Outside the Pharmacy Benefit With DirectAccess

Employer healthcare unbundling is moving into one of the most expensive and closely watched drug categories.

On September 15, Navitus launched GLP-1 Pathways, including DirectAccess, an option that lets eligible members access direct-to-consumer pricing for weight-management GLP-1 medications outside the traditional pharmacy benefit.

The distinction matters. DirectAccess does not eliminate the PBM or replace the employer's pharmacy benefit generally. It creates a parallel purchasing pathway for a specific category of drugs — particularly for plan sponsors that are not ready to add weight-management GLP-1 coverage to the conventional pharmacy benefit.

That makes the launch another meaningful example of employers being given infrastructure to purchase selected healthcare services outside the traditional health-plan and PBM transaction.

A third option between coverage and no coverage

The GLP-1 debate has often been framed as a binary decision: cover weight-management drugs through the pharmacy benefit or exclude them.

DirectAccess introduces another structure.

Navitus says the program gives eligible members access to direct-to-consumer pricing for weight-management GLP-1s while enabling predictable, fixed spending for plan sponsors. Its accompanying employer materials describe the approach as an off-benefit option for organizations that want to respond to member demand without adding full weight-management GLP-1 coverage to the pharmacy benefit.

The important economic point is the spending structure, not a promise that the employer absorbs the full drug cost. Navitus is positioning DirectAccess as a way for a plan sponsor to make a defined, fixed investment while members use the DTC purchasing channel, rather than exposing the plan to the utilization-driven claims expense of conventional coverage.

Navitus has not publicly disclosed the employer contribution amount or detailed pricing mechanics in the launch announcement, so those economics should be evaluated client by client. For more context on the underlying cost problem, see DirectContract's employer guide to weight-management GLP-1 costs.

This is employer healthcare unbundling

DirectContract has been tracking the same architecture across multiple categories.

GoodRx Employer Direct creates an employer-sponsored cash-pay pathway for selected medications and other services. VensureHR Direct Care packages primary care through a flat membership outside conventional fee-for-service claims. World Class Health's infusion model reflects the push to redirect specialty care toward lower-cost sites. Nara Health is building TPA infrastructure designed to administer plans that can combine direct contracts, cash pay, reference pricing and other alternative arrangements.

Centers of excellence, specialty carve-outs, infusion and site-of-care strategies, direct primary care and cash-pay programs all follow a related logic: the employer does not have to purchase every category of healthcare through one bundled insurance channel.

DirectAccess applies that logic inside pharmacy.

The employer can retain a PBM for the broad prescription benefit while creating a separate purchasing pathway for weight-management GLP-1s. That is unbundling at the category level, not wholesale PBM replacement.

The scale makes the signal more important

This is not a small benefits startup testing an alternative model.

Navitus says its PBM serves more than 13 million lives nationwide. The broader Navitus Health Solutions organization — including Navitus, Lumicera, Archimedes and Clarventa — reports serving nearly 20 million lives across 800 clients.

That distribution matters because it puts an off-benefit DTC pathway inside an organization already operating at substantial PBM scale.

It also suggests that parallel purchasing channels are becoming part of the product architecture of incumbent benefits organizations, not merely alternatives built outside them.

The PBM can participate in its own unbundling

That may be the most interesting part of the launch.

Employer healthcare unbundling is often described as a threat to incumbent carriers and PBMs. But incumbents can also build the infrastructure that allows employers to route selected categories differently.

Navitus is still the PBM. It is simply acknowledging that, for some plan sponsors and some drugs, the best available purchasing architecture may sit outside the traditional pharmacy benefit.

That mirrors what is happening elsewhere in employer healthcare. A broad medical plan can coexist with direct primary care. A carrier network can coexist with a surgery COE. A pharmacy benefit can coexist with specialty carve-outs or cash-pay pathways. An employer can use insurance for risk protection while purchasing selected, more predictable categories through separate channels.

The architecture becomes modular.

What employers should watch

The next questions are operational and economic.

Employers should understand the exact fixed-spending commitment, the member's net price, which FDA-approved weight-management GLP-1s are available, how eligibility and clinical support work, whether DTC spending interacts with deductibles or out-of-pocket limits, and how utilization outside the benefit is reflected in employer reporting and care coordination.

Those details will determine how attractive DirectAccess is relative to conventional coverage, exclusion, manufacturer-direct programs or other cash-pay options.

But the strategic signal is already clear: GLP-1 purchasing no longer has to be an all-or-nothing pharmacy-benefit decision.

Navitus is giving employers another channel.

And as employers assemble more of these channels across pharmacy, primary care, specialty care, infusion, surgery and other high-cost categories, the health plan increasingly looks less like a single bundled product and more like a portfolio of purchasing strategies.

Sources

• Navitus Health Solutions, “Navitus Launches GLP-1 Pathways and DirectAccess,” September 15, 2026: https://navitus.com/press-release/navitus-launches-glp-1-pathways-and-directaccess/
• Navitus, “The GLP-1 Market Is Loud, and Employers Need Clarity,” September 14, 2026.

DirectAccess is a platform/product launch, not a named signed employer direct contract. Employer-specific pricing, adoption and covered lives were not disclosed in the primary announcement.